RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia

[1]  E. Gilson,et al.  Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia. , 2023, Cell stem cell.

[2]  Francine E. Garrett-Bakelman,et al.  Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia , 2022, Science Translational Medicine.

[3]  D. Starczynowski,et al.  Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS , 2021, The Journal of experimental medicine.

[4]  Nicholas D. Camarda,et al.  Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome , 2021, Nature Communications.

[5]  C. Leslie,et al.  Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. , 2021, Cell stem cell.

[6]  G. Daley,et al.  An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation. , 2020, Blood advances.

[7]  A. Schambach,et al.  Cooperating, congenital neutropenia–associated Csf3r and Runx1 mutations activate pro-inflammatory signaling and inhibit myeloid differentiation of mouse HSPCs , 2020, Annals of Hematology.

[8]  R. Lindsley,et al.  Clonal hematopoiesis in the inherited bone marrow failure syndromes. , 2020, Blood.

[9]  G. Wertheim,et al.  Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling. , 2020, Blood advances.

[10]  A. Wang,et al.  Overcoming adaptive therapy resistance in AML by targeting immune response pathways , 2019, Science Translational Medicine.

[11]  Donna Neuberg,et al.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies , 2019, Science.

[12]  J. Abkowitz,et al.  Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. , 2019, Blood.

[13]  K. Pradhan,et al.  U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies , 2019, Nature Cell Biology.

[14]  A. Shimamura,et al.  Genetic predisposition to MDS: clinical features and clonal evolution. , 2019, Blood.

[15]  T. Tan,et al.  RUNX Poly(ADP-Ribosyl)ation and BLM Interaction Facilitate the Fanconi Anemia Pathway of DNA Repair. , 2018, Cell reports.

[16]  Samuel H. Payne,et al.  Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes , 2018, Leukemia.

[17]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[18]  G. Nalepa,et al.  Fanconi anaemia and cancer: an intricate relationship , 2018, Nature Reviews Cancer.

[19]  M. Wlodarski,et al.  Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms , 2017, Klinische Pädiatrie.

[20]  J. Aster,et al.  Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. , 2017, Cell stem cell.

[21]  Davis J. McCarthy,et al.  Common genetic variation drives molecular heterogeneity in human iPSCs , 2017, Nature.

[22]  A. F. Stewart,et al.  DNA Damage-Induced HSPC Malfunction Depends on ROS Accumulation Downstream of IFN-1 Signaling and Bid Mobilization. , 2016, Cell stem cell.

[23]  P. Kurre,et al.  Endogenous DNA Damage Leads to p53-Independent Deficits in Replicative Fitness in Fetal Murine Fancd2−/− Hematopoietic Stem and Progenitor Cells , 2016, Stem cell reports.

[24]  J. Soulier,et al.  How I treat MDS and AML in Fanconi anemia. , 2016, Blood.

[25]  J. Soulier,et al.  TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. , 2016, Cell stem cell.

[26]  K. Wikenheiser-Brokamp,et al.  Overcoming Pluripotent Stem Cell Dependence on the Repair of Endogenous DNA Damage , 2016, Stem cell reports.

[27]  Long Gao,et al.  Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. , 2015, Cell stem cell.

[28]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[29]  D. Kraft,et al.  NF-κB-dependent DNA damage-signaling differentially regulates DNA double-strand break repair mechanisms in immature and mature human hematopoietic cells , 2015, Leukemia.

[30]  D. Bluteau,et al.  Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. , 2015, Blood.

[31]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[32]  T. Tan,et al.  Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. , 2014, Cell reports.

[33]  G. Keller,et al.  Wnt Signaling Controls the Specification of Definitive and Primitive Hematopoiesis From Human Pluripotent Stem Cells , 2014, Nature Biotechnology.

[34]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[35]  Michael R. Garbati,et al.  FANCA and FANCC modulate TLR and p38 MAPK-dependent expression of IL-1β in macrophages. , 2013, Blood.

[36]  James J Collins,et al.  Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. , 2013, Cell stem cell.

[37]  Lesley A. Mathews,et al.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. , 2013, Cancer cell.

[38]  H. Deeg,et al.  Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Kurre,et al.  Fetal origins of hematopoietic failure in a murine model of Fanconi anemia. , 2013, Blood.

[40]  J. Soulier,et al.  Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. , 2012, Cell stem cell.

[41]  David A. Williams,et al.  Overcoming reprogramming resistance of Fanconi anemia cells. , 2012, Blood.

[42]  I. Matsumura,et al.  C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells , 2012, Leukemia.

[43]  L. Wiesmüller,et al.  NF-κB regulates DNA double-strand break repair in conjunction with BRCA1–CtIP complexes , 2011, Nucleic acids research.

[44]  F. Sigaux,et al.  Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. , 2011, Blood.

[45]  J. Soulier,et al.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. , 2011, The Journal of clinical investigation.

[46]  G. Daley,et al.  Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. , 2010, Blood.

[47]  Jane Yates,et al.  TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. , 2009, Blood.

[48]  A. D’Andrea,et al.  Mouse models of Fanconi anemia. , 2009, Mutation research.

[49]  P. Rosenberg,et al.  Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry , 2008, Haematologica.

[50]  P. Andreassen,et al.  p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. , 2007, Blood.

[51]  Q. Waisfisz,et al.  Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. , 2003, Cancer research.

[52]  John T. Dimos,et al.  A Stem Cell Molecular Signature , 2002, Science.

[53]  J. Wagner,et al.  Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  B. Alter,et al.  Fanconi anemia: myelodysplasia as a predictor of outcome. , 2000, Cancer genetics and cytogenetics.

[55]  C. McKerlie,et al.  Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage. , 1998, Blood.

[56]  R. Parshad,et al.  Chromosomal radiosensitivity during the G2 cell-cycle period of skin fibroblasts from individuals with familial cancer. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Wagner,et al.  Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics. , 2010, American journal of clinical pathology.

[58]  R. G. Allen,et al.  Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. , 1991, Cancer genetics and cytogenetics.